Canadian drug discovery technology company AbCellera, which analyzes and identifies antibodies for pharmaceutical companies working on a coronavirus treatment and other medicines, said on Wednesday it had raised $105 million in funds.
AbCellera has been working with pharmaceutical firm Eli Lilly and Co which is developing a coronavirus drug based on antibodies from patients that have recovered from the disease.
The human sample is inserted into a device the size of a credit card that has over 250,000 “chambers.” A computer checks human antibodies secreted into the chambers by sample cells to determine which has the best properties for fighting a certain disease and is worth developing, he said. Funds raised through AbCellera’s latest funding round will be used to hire about 100 more employees, mostly in software and data science, Hansen said, adding that the company currently has 140 employees and plans to open a new 48,000-square-foot R&D facility next year.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Here's What We Actually Know About How Long COVID-19 Antibodies Could LastWhile studies of similar viruses suggest that antibodies could last two to three years, it's not yet known whether the same is true for COVID-19.
Read more »
CDC Says Possibly 'Less Than Half' Of Positive Antibody Tests Are CorrectThe CDC has acknowledged that antibody tests used to determine if people have previously been infected with Covid-19 are not accurate enough to guide important policy decisions.
Read more »
Opinion: Sharing your job with a coworker could help prevent more mass layoffs'One way to reduce the economic damage may be job-sharing, an approach that focuses on maximizing jobs by reducing workers' hours rather than resorting to layoffs or furloughs,' Jason Ward writes for CNNBusiness Perspectives.
Read more »
Questions about COVID-19 test accuracy raised across the testing spectrumDiagnostic tests are no longer in short supply, but questions about their accuracy are growing.
Read more »
Coronavirus ‘silent spreaders’ become a bigger risk as California reopensThere’s increasing concern that people infected with COVID-19 who show no signs of illness are playing a large role in the transmission of COVID-19.
Read more »
Japan gives up approving Fujifilm's Avigan drug for COVID-19 by May-end: KyodoJapan's government has given up on approving Fujifilm Holdings Corp's Avigan drug for the treatment of COVID-19 by the end of May, Kyodo News reported late on Monday citing a government official.
Read more »